BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 12084931)

  • 21. Urokinase-type plasminogen activator.
    Crippa MP
    Int J Biochem Cell Biol; 2007; 39(4):690-4. PubMed ID: 17118695
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Arsenic trioxide (As2O3) inhibits invasion of HT1080 human fibrosarcoma cells: role of nuclear factor-kappaB and reactive oxygen species.
    Park MJ; Lee JY; Kwak HJ; Park CM; Lee HC; Woo SH; Jin HO; Han CJ; An S; Lee SH; Chung HY; Park IC; Hong SI; Rhee CH
    J Cell Biochem; 2005 Aug; 95(5):955-69. PubMed ID: 15962302
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of hypoxia and reoxygenation on the expression levels of the urokinase-type plasminogen activator, its inhibitor plasminogen activator inhibitor type-1 and the urokinase-type plasminogen activator receptor in human head and neck tumour cells.
    Sprague LD; Tomaso H; Mengele K; Schilling D; Bayer C; Stadler P; Schmitt M; Molls M
    Oncol Rep; 2007 May; 17(5):1259-68. PubMed ID: 17390074
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder.
    Bhuvarahamurthy V; Schroeder J; Denkert C; Kristiansen G; Schnorr D; Loening SA; Jung K; Staack A
    Oncol Rep; 2004 Oct; 12(4):909-13. PubMed ID: 15375521
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The urokinase-type plasminogen activator, its receptor and u-PA inhibitor type-1 affect in vitro growth and invasion of Kaposi's sarcoma and capillary endothelial cells: role of HIV-Tat protein.
    Margheri F; D'Alessio S; Serratì S; Pucci M; Del Rosso A; Benelli R; Ferrari N; Noonan DM; Albini A; Fibbi G; Del Rosso M
    Int J Oncol; 2005 Jul; 27(1):223-35. PubMed ID: 15942664
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
    Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
    J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activation of urokinase receptor by a novel interaction between the connecting peptide region of urokinase and alpha v beta 5 integrin.
    Franco P; Vocca I; Carriero MV; Alfano D; Cito L; Longanesi-Cattani I; Grieco P; Ossowski L; Stoppelli MP
    J Cell Sci; 2006 Aug; 119(Pt 16):3424-34. PubMed ID: 16882693
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling.
    Xue A; Xue M; Jackson C; Smith RC
    Int J Biochem Cell Biol; 2009; 41(8-9):1731-8. PubMed ID: 19433314
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Urokinase plasminogen activator upregulates paraoxonase 2 expression in macrophages via an NADPH oxidase-dependent mechanism.
    Fuhrman B; Khateeb J; Shiner M; Nitzan O; Karry R; Volkova N; Aviram M
    Arterioscler Thromb Vasc Biol; 2008 Jul; 28(7):1361-7. PubMed ID: 18436804
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mitogenic signaling of urokinase receptor-deficient kidney fibroblasts: actions of an alternative urokinase receptor and LDL receptor-related protein.
    Zhang G; Cai X; López-Guisa JM; Collins SJ; Eddy AA
    J Am Soc Nephrol; 2004 Aug; 15(8):2090-102. PubMed ID: 15284295
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High urokinase expression contributes to the angiogenic properties of endothelial cells derived from circulating progenitors.
    Basire A; Sabatier F; Ravet S; Lamy E; Mialhe A; Zabouo G; Paul P; Gurewich V; Sampol J; Dignat-George F
    Thromb Haemost; 2006 Apr; 95(4):678-88. PubMed ID: 16601839
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-mobility group box 1 protein induces HIV-1 expression from persistently infected cells.
    Thierry S; Gozlan J; Jaulmes A; Boniface R; Nasreddine N; Strauss F; Maréchal V
    AIDS; 2007 Jan; 21(3):283-92. PubMed ID: 17255735
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R; Schaaf A
    Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors.
    Gutova M; Najbauer J; Frank RT; Kendall SE; Gevorgyan A; Metz MZ; Guevorkian M; Edmiston M; Zhao D; Glackin CA; Kim SU; Aboody KS
    Stem Cells; 2008 Jun; 26(6):1406-13. PubMed ID: 18403751
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibitory effect of a synthetic prostacyclin analogue, beraprost, on urokinase-type plasminogen activator expression in RC-K8 human lymphoma cells.
    Nomura N; Niiya K; Shinbo M; Ozawa T; Hayakawa Y; Higashiyama K; Fujimaki M; Sakuragawa N
    Thromb Haemost; 1996 Jun; 75(6):928-32. PubMed ID: 8822588
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EGF-stimulated migration in ovarian cancer cells is associated with decreased internalization, increased surface expression, and increased shedding of the urokinase plasminogen activator receptor.
    Henic E; Sixt M; Hansson S; Høyer-Hansen G; Casslén B
    Gynecol Oncol; 2006 Apr; 101(1):28-39. PubMed ID: 16263158
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential localization and expression of urokinase plasminogen activator (uPA), its receptor (uPAR), and its inhibitor (PAI-1) mRNA and protein in endometrial tissue during the menstrual cycle.
    Nordengren J; Pilka R; Noskova V; Ehinger A; Domanski H; Andersson C; Høyer-Hansen G; Hansson SR; Casslén B
    Mol Hum Reprod; 2004 Sep; 10(9):655-63. PubMed ID: 15243126
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of cerebrospinal fluid uPA, PAI-1, and soluble uPAR levels in HIV-infected patients.
    Sporer B; Koedel U; Popp B; Paul R; Pfister HW
    J Neuroimmunol; 2005 Jun; 163(1-2):190-4. PubMed ID: 15885322
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Natural killer cell inhibits human immunodeficiency virus replication in chronically infected immune cells.
    Zhang T; Li Y; Wang YJ; Wang X; Young M; Douglas SD; Ho WZ
    Antiviral Res; 2007 Feb; 73(2):132-9. PubMed ID: 16997390
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interaction between cancer cells and stromal fibroblasts is required for activation of the uPAR-uPA-MMP-2 cascade in pancreatic cancer metastasis.
    He Y; Liu XD; Chen ZY; Zhu J; Xiong Y; Li K; Dong JH; Li X
    Clin Cancer Res; 2007 Jun; 13(11):3115-24. PubMed ID: 17545513
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.